venBio Partners

Latest statistics and disclosures from venBio Partners's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are ALXO, PHVS, HRMY, SLRN, ELEV, and represent 100.00% of venBio Partners's stock portfolio.
  • Reduced shares in these 4 stocks: Rayzebio (-$321M), PHVS (-$15M), ELEV, IMPLQ.
  • Sold out of its positions in IMPLQ, Rayzebio.
  • venBio Partners was a net seller of stock by $-337M.
  • venBio Partners has $282M in assets under management (AUM), dropping by -57.75%.
  • Central Index Key (CIK): 0001776382

Tip: Access up to 7 years of quarterly data

Positions held by venBio Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for venBio Partners

venBio Partners holds 5 positions in its portfolio as reported in the March 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Alx Oncology Hldgs (ALXO) 38.4 $108M 9.7M 11.15
 View chart
Pharvaris N V (PHVS) 35.2 $99M -12% 4.3M 23.11
 View chart
Harmony Biosciences Hldgs In (HRMY) 12.3 $35M 1.0M 33.58
 View chart
Acelyrin (SLRN) 9.2 $26M 3.9M 6.75
 View chart
Elevation Oncology (ELEV) 4.9 $14M -7% 2.7M 5.13
 View chart

Past Filings by venBio Partners

SEC 13F filings are viewable for venBio Partners going back to 2019

View all past filings